Evidence map›Paper›PMID 33802285›Full record

ArticleVaccines2021

Acceptance of a COVID-19 Vaccine in Japan during the COVID-19 Pandemic.

Masaki Machida, Itaru Nakamura, Takako Kojima, Reiko Saito, Tomoki Nakaya, Tomoya Hanibuchi, Tomoko Takamiya, Yuko Odagiri, Noritoshi Fukushima, Hiroyuki Kikuchi and 3 more

Abstract read
In one paragraph

Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Masaki MachidaDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo 160-8402, Japan.ORCID 0000-0002-7060-7305
Itaru NakamuraDepartment of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo 160-0023, Japan.
Takako KojimaDepartment of International Medical Communications, Tokyo Medical University, Tokyo 160-0023, Japan.
Reiko SaitoDivision of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata 951-8510, Japan.
Tomoki NakayaGraduate School of Environmental Studies, Tohoku University, Miyagi 980-0845, Japan.
Tomoya HanibuchiGraduate School of Environmental Studies, Tohoku University, Miyagi 980-0845, Japan.ORCID 0000-0002-0447-7645
Tomoko TakamiyaDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo 160-8402, Japan.
Yuko OdagiriDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo 160-8402, Japan.
Noritoshi FukushimaDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo 160-8402, Japan.
Hiroyuki KikuchiDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo 160-8402, Japan.ORCID 0000-0003-0510-1030
Shiho AmagasaDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo 160-8402, Japan.ORCID 0000-0002-6047-0771
Hidehiro WatanabeDepartment of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo 160-0023, Japan.
Shigeru InoueDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo 160-8402, Japan.ORCID 0000-0003-1931-2613

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vaccination could be a key protective measure against coronavirus disease 2019 (COVID-19), and it is important to understand the acceptability of the COVID-19 vaccine among the general public. However, there is no study on the acceptance of a COVID-19 vaccine in Japan. Therefore, this study aimed to describe the COVID-19 vaccine acceptance and hesitancy situation in Japan and assess the factors associated with such issues. This was a cross-sectional study based on an internet survey completed by 2956 people. Participants were asked to indicate how likely they were to get vaccinated for COVID-19. In addition, the participants responded to questions regarding sociodemographic factors, attitudes, and beliefs regarding COVID-19 infection and vaccination. The proportion of participants with a high likelihood of getting a COVID-19 vaccine was 62.1%. Multiple logistic regression analysis showed that vaccine acceptance was lower among several sociodemographic groups, such as women, adults aged 20-49 years, and those with a low-income level. Several psychological factors, especially the perceived effectiveness of the COVID-19 vaccine, and willingness to protect others by getting oneself vaccinated, were associated with vaccine acceptance. Our results indicate that the perceived effectiveness of the vaccine and willingness to protect others may play an important role in the acceptance of the COVID-19 vaccine.

Indexed as

COVID-19epidemiologypublic healthvaccinevaccine hesitancy

Identifiers

PMID33802285
PMCPMC8002097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.